Navigation Links
Adult COPD or asthma could be effectively treated with Xopenex

COPD - Chronic Obstructive Pulmonary Disease - including chronic bronchitis and emphysema, is characterized by breathing difficulty due to partial blockage of the bronchial tubes. Asthma is a chronic lung disease caused by inflammation of the lower airways resulting in episodes of airflow obstruction, which has been found to be the fourth most common// cause of death and affects nearly 16 million people in the United States. According to the American Lung Association, it is the most common childhood illness and affects approximately 8.6 million children under the age of 18.

A new study conducted at the Halifax Regional Hospital in South Boston, suggested Xopenex as a viable first-line therapy for hospitalized adult COPD or asthma patients. Lead author of the study, Terrance Truitt said that Xopenex is safe in a hospital setting, and is an effective alternative to racemic albuterol in treating the bronchial smooth muscle spasm associated with diseases such as COPD and asthma. The study involved the comparison of the treatment of 231 patients with similar background and disease conditions over two separate six-month periods. The first group had been treated with the previous standard treatment, the second group with Xopenex. It was found that the subjects showed significant symptom improvement and a change in the frequency of nebulizer treatments - in intervals of 6 to 8 hours. This change was achieved with a 1.25 mg dose of Xopenex. In addition, the Xopenex group needed only 2.0 +/- 2.6 days of ipratropium bromide treatments. Patients receiving Xopenex were found to require significantly less nebulizer therapy and less adjuvant respiratory therapy, according to the study.

Xopenex is being marketed as a nebulizer at dosage strengths of 0.31 mg and 0.63 mg for pediatric patients and as 0.63 mg and 1.25 mg for patients 12 years of age and older. Xopenex brand levalbuterol HCl inhalation solution is indicated for the treatment or prevention of bronc hospasm in patients 6 years and older with reversible obstructive airway disease, such as asthma.


'"/>




Related medicine news :

1. Baby Talk Better Than Adult Speech
2. A question on study of Adult Stem Cell
3. Adult stem cells in treatment for Multiple sclerosis (MS)
4. The Key To Prevention Of Heart Disease In Adults
5. The Harmful Effects Of Stress in Young Adults
6. Abuse in Childhood Could Result In Heart Disease in Adulthood
7. Adult bone health is dependent on lifestyle we live
8. Adult Stem Cells From Fat Tissues For Healing
9. Obese Adults Undergo Less Medical Tests And More Vulnerable To Diseases
10. A New Technique For Prediction Of Adult Height
11. New Drug Found To Improve Driving Performance In Young Adults With ADHD
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... ... 2016 , ... CloudLIMS.com, a class-leading provider of Laboratory Management ... Lite helps biobanks, clinical, research and testing laboratories keep track of their biospecimens, ... is a faster and a more efficient product, allowing batch processing of data, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Yisrayl Hawkins, at The House ... this current generation fits into Bible Prophecy. Yisrayl says this generation, known as the ... this conclusion, showing how the details line up exactly with Bible Prophecy – a ...
(Date:12/2/2016)... Pass, OR (PRWEB) , ... December 02, 2016 ... ... Wein, Medical Technologist/Clinical Laboratory Scientist & Author of Type 2 Diabetes: The Owner’s ... host of The Sharon Kleyne Hour Power of Water, Global Climate Change and ...
(Date:11/30/2016)... PALMYRA, Wisconsin (PRWEB) , ... November 30, 2016 ... ... inclusion in the 2016 Deloitte Wisconsin 75, an annual ranking and recognition of ... consecutive year on the list, having ranked from 2008-2016. In addition, Standard Process ...
(Date:11/30/2016)... ... November 30, 2016 , ... The ... community that the FDA Binding Guidance goes into effect next month. Sponsors whose ... in the FDA Data Standards Catalog. The current FDA Data Standards Catalog specifies ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2, 2016   CytoSorbents Corporation (NASDAQ: ... European Union approved CytoSorb ® cytokine adsorber to ... worldwide, announced that Dr. Phillip Chan , Chief ... LD Micro Main Event investor conference held from ... Luxe Sunset Boulevard Hotel in Los Angeles, ...
(Date:12/2/2016)... Research and Markets has announced the addition of Jain ... and Companies" to their offering. ... , , Drug ... market value of drug delivery technologies and the anticancer drugs are ... to organs involved and the types of cancer as well as ...
(Date:12/2/2016)... Around the corners of world, cancer has infused itself ... over earth. Cancer has become one of those nightmares ... this is because of the increasing incidence rates and ... increase in global cancer incidence with its associated morbidity ... treatment, there is increasing interest in this stringent disease. ...
Breaking Medicine Technology: